Pharmacokinetics of levofloxacin in hemodialyzed patients.

DOI 2 Citations 8 References

Bibliographic Information

Other Title
  • 血液透析患者におけるレボフロキサシンの薬動力学

Search this article

Abstract

Levofloxacin (LVFX) is a new antibacterial agent derived from ofloxacin (OFLX). We measured and compared the growth inhibitory rings for several bacterial strains for each drug and also studied the pharmacokinetics of LVFX in patients undergoing hemodialysis (HD). The growth inhibitory ring of LVFX was about one and half times as large as that of OFLX. We monitored the serum concentration of LVFX during HD therapy in 13 patients after oral administration of 100mg LVFX, to obtain the biological half life time (T1/2), clearance (CLLVFX) and sieving coefficient (SCLVFX). The maximum LVFX concentration was 1.59μg/ml just before HD and had decreased to 0.99μg/ml by 4 hours of continuous HD therapy. CLLVFX, SCLVFX and T1/2 were 113.6ml/min, 0.74 and 6.3 hours, respectively, under the condition of HD therapy and T1/2 was 55.4 hours on a nondialyzed day. There was no significant difference in CLLVFX between polysulfone and cellulose triacetate membranes. The HD patients received HD therapy every other day, allowing calculation of the recommended dosage of LVFX, 100mg once a day for 4 days, from the multiple-dose study.

Journal

Citations (2)*help

See more

References(8)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top